RESPONSE-2 5-year follow-up update: ruxolitinib vs BAT in polycythemia vera without splenomegaly VJHemOnc – Video Journal of Hematology & HemOnc 1:23 2 years ago 143 Далее Скачать
RESPONSE-2: 5-year follow-up of second-line ruxolitinib therapy for PV VJHemOnc – Video Journal of Hematology & HemOnc 1:32 3 years ago 83 Далее Скачать
Updated Findings After 5-Year Follow-Up for Ruxolitinib in PV Targeted Oncology 1:13 5 years ago 140 Далее Скачать
Long-term 5-year data continues to show RESPONSE to ruxolitinib in polycythemia vera VJHemOnc – Video Journal of Hematology & HemOnc 2:14 5 years ago 220 Далее Скачать
Results for the follow-up of the RESPONSE study VJHemOnc – Video Journal of Hematology & HemOnc 1:46 9 years ago 66 Далее Скачать
A RESPONSE to ruxolitinib: update on 4-year trial follow-up VJHemOnc – Video Journal of Hematology & HemOnc 3:34 6 years ago 254 Далее Скачать
Results from the MAJIC-PV trial: ruxolitinib vs BAT for hydroxyurea resistant/intolerant PV VJHemOnc – Video Journal of Hematology & HemOnc 3:06 1 year ago 903 Далее Скачать
Understanding the Importance of Baseline Patient Features in the RESPONSE-2 Study MPNUniversity .tv 7:19 7 years ago 202 Далее Скачать
REVEAL study: long-term analysis of ruxolitinib in patients with polycythemia vera after hydroxyurea VJHemOnc – Video Journal of Hematology & HemOnc 0:52 1 year ago 1 016 Далее Скачать
Ruxolitinib Patient Selection in Polycythemia Vera Targeted Oncology 6:39 8 years ago 113 Далее Скачать
Follow up of the phase 3 RESPONSE trial of ruxolitinib in polycythemia vera EMJ 1:44 9 years ago 106 Далее Скачать
Ruxolitinib in combination with abemaciclib for patients with primary or post-PV/ET myelofibrosis VJHemOnc – Video Journal of Hematology & HemOnc 2:51 1 year ago 163 Далее Скачать
The 5-year update on the COMFORT-II clinical trial of ruxolitinib VJHemOnc – Video Journal of Hematology & HemOnc 2:49 8 years ago 301 Далее Скачать
MAJIC update: promising results for ruxolitinib in PV and ET VJHemOnc – Video Journal of Hematology & HemOnc 2:09 6 years ago 429 Далее Скачать
Further Analysis of RESPONSE Trial Data Validates Ruxolitinib as Second-Line Therapy OncLive 3:07 9 years ago 335 Далее Скачать
